Received Jul 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | AMVB064A | IM |
patient received the liquid conjugate component only for Menveo; patient received the liquid conjugate component only for Menveo; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate preparation of medication in a 9-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVB064A, expiry date 31-DEC-2025) for prophylaxis. Concomitant products included DIPHTHERIA VACCINE TOXOID;PERTUSSIS VACCINE ACELLULAR 3-COMPONENT;TETANUS VACCINE TOXOID (BOOSTRIX) and HPV VACCINE VLP RL1 9V (YEAST) (GARDASIL 9). On 15-JUL-2025, the patient received the 1st dose of Menveo (intramuscular). On 15-JUL-2025, an unknown time after receiving Menveo, the patient experienced inappropriate preparation of medication (Verbatim: patient received the liquid conjugate component only for Menveo) and inappropriate dose of vaccine administered (Verbatim: patient received the liquid conjugate component only for Menveo). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 17-JUL-2025 and 17-JUL-2025 The reporter was a nurse who called to report that a male patient had received only the liquid conjugate component of Menveo in his left leg on 15th July 2025, which led to Inappropriate preparation of medication and Inappropriate dose of vaccine administered. The patient had also received Boostrix and Gardasil 9 at the same visit on 15th July 2025. All the information that was provided about this adverse event was reported.; Sender's Comments: US-GSK-US2025091789:same reporter, Different patient
BOOSTRIX; GARDASIL 9